The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenues | 874,837 | 450,712 | - | - |
| Cost of product sales | 19,075 | 12,269 | - | - |
| Research and development (excluding stock-based compensation)-Berotralstat | 12,148 | 45,033 | - | - |
| Research and development (excluding stock-based compensation)-BCX17725 | 17,304 | 32,417 | - | - |
| Research and development (excluding stock-based compensation)-Avoralstat | 9,497 | - | - | - |
| Research and development (excluding stock-based compensation)-Factor DProgram | 456 | 24,072 | - | - |
| Research and development (excluding stock-based compensation)-Research Discovery And Preclinical Programs | 17,677 | - | - | - |
| Research and development (excluding stock-based compensation)-Compensation And Related Personnel Costs | 51,576 | - | - | - |
| Research and development-Other Research Preclinical And Development Costs | - | 73,116 | - | - |
| Research and development (excluding stock-based compensation)-Other Expenses1 | 27,958 | - | - | - |
| Selling, general and administrative | - | 266,132 | - | - |
| Sales and marketing (excluding stock-based compensation) | 177,085 | - | - | - |
| Royalty | - | 216 | - | - |
| General and administrative (excluding stock-based compensation) | 116,006 | - | - | - |
| Other segment items | - | 641 | - | - |
| Stock-based compensation | 85,066 | - | - | - |
| Interest income | 10,668 | 14,746 | - | - |
| Interest expense | 78,872 | 98,516 | - | - |
| Foreign currency losses, net | -152 | - | - | - |
| Loss on extinguishment of debt | -17,332 | - | - | - |
| Other income | 12,090 | - | - | - |
| Income tax expense | 3,530 | 1,927 | - | - |
| Net income (loss) | 263,861 | -88,881 | -226,539 | -247,116 |
| Depreciation and amortization | 1,389 | 1,246 | 1,655 | 1,437 |
| Inventory obsolescence | 985 | 1,350 | 422 | 932 |
| Stock-based compensation expense | 85,066 | 65,413 | 55,615 | 44,701 |
| Equity modification associated with sale of biocryst ireland | 17,548 | - | - | - |
| Mark-to-market adjustment on share-based liability | 4,313 | - | - | - |
| Payment of pharmakon pik interest | 23,704 | - | - | - |
| Non-cash interest expense on royalty financing obligations | 53,163 | - | - | - |
| Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs | - | - | 85,803 | 98,918 |
| Non-cash interest expense on secured term loan and amortization of debt issuance costs | 1,387 | 67,607 | - | - |
| Amortization of discount on investments, net | -4,331 | -11,473 | -10,263 | -1,777 |
| Loss on extinguishment of debt | -17,332 | 0 | -29,019 | - |
| Loss on impairment | 0 | 0 | 1,548 | - |
| Change in fair value of foreign currency derivative | - | - | - | 0 |
| Gain on sale of non-financial asset | 550 | - | - | - |
| (gain) loss on extinguishment of debt | - | - | - | 0 |
| Gain on sale of biocryst ireland | 3,566 | - | - | - |
| Increase in receivables | 36,806 | 22,698 | 6,095 | 21,470 |
| Increase in inventory | 1,639 | 4,164 | 1,450 | 12,423 |
| (increase) decrease in prepaid expenses and other assets | 7,827 | -1,959 | 6,820 | 2,583 |
| Decrease in royalty financing obligations | 68,428 | - | - | - |
| Increase in accounts payable and accrued expenses | 57,802 | -62,379 | -16,806 | -22,360 |
| Interest payable | - | - | 0 | 0 |
| Decrease in deferred revenue | 0 | 0 | -1,230 | -109 |
| Net cash provided by (used in) operating activities | 347,369 | -52,020 | -95,141 | -161,850 |
| Acquisitions of property and equipment | 2,468 | 1,124 | 2,168 | 1,351 |
| Purchases of investments | 262,240 | 266,763 | 514,407 | 244,283 |
| Sales and maturities of investments | 256,647 | 320,480 | 385,077 | 117,396 |
| Sale of non-financial asset | 550 | - | - | - |
| Proceeds from sale of biocryst ireland, net of cash divested | -6,183 | - | - | - |
| Net cash (used in) provided by investing activities | -13,694 | 52,593 | -131,498 | -128,238 |
| Sale of common stock, net | - | - | 0 | 0 |
| Net proceeds from common stock issued under stock-based compensation plans | 9,115 | 3,444 | 8,340 | - |
| Withholding taxes paid on stock-based awards | 8,847 | 7,535 | 2,172 | - |
| Common stock issued to directors in lieu of cash retainer | 59 | 34 | 342 | - |
| Net proceeds from term loans | 0 | 0 | 300,000 | - |
| Repayment of athyrium secured term loans principal | - | 0 | 240,452 | - |
| Repayment of principal on term loans | 300,000 | - | - | - |
| Prepayment and repayment fees on athyrium secured term loans | - | 0 | 21,261 | - |
| Prepayment premium and fees on term loans | 9,886 | - | - | - |
| Payment of debt issuance costs on pharmakon tranche a term loan | 0 | 0 | 11,147 | - |
| Principal payments on royalty financing obligations | 22,883 | - | - | - |
| Sale of pre-funded warrants | - | - | - | 0 |
| Net proceeds from common stock issued under stock-based compensation plans | - | - | - | 14,955 |
| Proceeds from additional credit facility | - | - | - | 73,072 |
| Payment of senior credit facility | - | - | - | 0 |
| Payment of royalty release fees | 15,500 | - | - | - |
| Net proceeds from secured term loan | - | - | - | 0 |
| Principal payments on finance lease liabilities | 1,989 | 1,704 | 1,165 | - |
| Net proceeds from royalty financing liabilities | - | - | 0 | 0 |
| Net cash (used in) provided by financing activities | -349,931 | -5,761 | 32,485 | 88,027 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 1,270 | -936 | 362 | 566 |
| Decrease in cash, cash equivalents and restricted cash | -14,986 | -6,124 | -193,792 | -201,495 |
| Cash, cash equivalents and restricted cash at beginning of year | - | 112,447 | 306,239 | 507,734 |
| Beginning of year | 106,323 | - | - | - |
| Cash, cash equivalents and restricted cash at end of year | - | 106,323 | 112,447 | 306,239 |
| End of year | 91,337 | - | - | - |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)